Bioshore closes Australia's first medtech-only VC fund at $27M
What's the deal? Bioshore VenturesDealroom has a profile for this one. Try Dealroom → is set to announce a final close on its debut fund at $27 million, with the capital already committed across eight early-stage companies. General partner Jeff Reid says the firm is Australia's only venture capital firm investing solely in medical technologies — physical devices and hardware, not drugs or treatments.
What's the endgame? Bioshore's thesis rests on medtech's narrower risk profile compared with biotech. Around 75% of medical technologies that reach human trials go on to be commercialised, versus just 8% of novel molecules developed by biotech firms.
Returns are lower than biotech's outliers but Reid puts them in the 5% to 25% range, pointing to Australian successes such as CochlearDealroom has a profile for this one. Try Dealroom → hearing implants and ResmedDealroom has a profile for this one. Try Dealroom → sleep apnea devices.
Who's backing it? The fund drew 65 investors, all high-net-worth individuals. Of those, 40 are surgeons and clinicians spanning vascular medicine, orthopedics, and cardiology; many provided specialist due diligence on prospective deals.
It also attracted private capital figures including Quadrant Private EquityDealroom has a profile for this one. Try Dealroom → managing partner Marcus Darville, Paradice InvestmentDealroom has a profile for this one. Try Dealroom → founder David Paradice, and Navis CapitalDealroom has a profile for this one. Try Dealroom → co-founder Rodney Muse.
The structure: Bioshore raised the fund under Early Stage Venture Capital Limited Partnership (ESVCLP) legislation, which requires a minimum of $10 million and caps funds at $200 million. Investors get a 10% carry-forward tax offset and are generally exempt from tax on income and capital gains from eligible disposals.
The investment team comprises three general partners: Reid, founder of several medical startups; Andrew Fox-Smith, former president, international, of Enovis Rehabilitation; and David Bottomley, co-founder of Ryder CapitalDealroom has a profile for this one. Try Dealroom → and managing general partner of the Ryder Innovation FundDealroom has a profile for this one. Try Dealroom →, another registered ESVCLP.
Where the money's going: Bioshore Fund 1 has backed companies including Leo Cancer Care, developing radiation therapy delivery technology; Remedy Robotics, building remotely operated cardiovascular surgery robots; Kitea Health, focused on hydrocephalus care; and VevexDealroom has a profile for this one. Try Dealroom →, which works on vascular imaging.
The signal: A first-time, single-sector fund built largely from clinician capital is a bet that medtech's more predictable commercialisation path and lighter regulatory thresholds can deliver steadier venture returns than the boom-or-bust biotech model.
Read more: privateequitymedia.com.au
Image credit: Generated with Gemini
